Seeking Alpha
26 Jul 2026, 13:46 UTC · 1h ago
Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
26 Jul 2026, 13:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Celldex's EMBARQ-CSU 1 and 2 phase 3 trials completed enrollment six months ahead of schedule. — Accelerated enrollment reduces the timeline to pivotal data and potential commercialization of the lead asset.
+0.60Pivotal data for barzolvolimab is expected in September/October 2026, with a potential BLA filing in 2027. — Establishes a clear, medium-term catalyst timeline for the company's primary value driver.
+0.40The company is advancing CDX-622, a bispecific TSLP & SCF inhibitor, with promising phase 1 safety and mechanism data. — Diversifies the pipeline beyond CSU, reducing single-asset binary risk.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company maintains a 'Strong Buy' rating due to rapid phase 3 enrollment and promising pipeline catalysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1d ago
